Insider Selling: Medifast (NYSE:MED) Director Sells $111,951.12 in Stock

Medifast Inc (NYSE:MED) Director Daniel Chard sold 9,544 shares of the company’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $11.73, for a total value of $111,951.12. Following the sale, the director directly owned 130,609 shares in the company, valued at approximately $1,532,043.57. This represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medifast Trading Down 0.7%

Medifast stock traded down $0.09 during mid-day trading on Wednesday, reaching $11.53. The company’s stock had a trading volume of 138,133 shares, compared to its average volume of 113,400. The firm has a market cap of $128.85 million, a price-to-earnings ratio of -4.95 and a beta of 0.71. The business has a 50 day moving average price of $11.67 and a 200-day moving average price of $11.34. Medifast Inc has a twelve month low of $9.22 and a twelve month high of $14.15.

Medifast (NYSE:MED) last issued its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. The company had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. On average, equities analysts expect that Medifast Inc will post -1.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on MED shares. Zacks Research cut shares of Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $12.00.

Institutional Investors Weigh In On Medifast

A number of hedge funds have recently added to or reduced their stakes in MED. State of Wyoming boosted its holdings in shares of Medifast by 19.8% during the first quarter. State of Wyoming now owns 6,646 shares of the specialty retailer’s stock valued at $68,000 after acquiring an additional 1,097 shares during the period. Ancora Advisors LLC acquired a new stake in shares of Medifast in the 2nd quarter worth about $75,000. Quantinno Capital Management LP increased its holdings in shares of Medifast by 15.1% in the 1st quarter. Quantinno Capital Management LP now owns 56,153 shares of the specialty retailer’s stock worth $572,000 after acquiring an additional 7,346 shares during the period. Engineers Gate Manager LP lifted its position in Medifast by 25.9% in the 2nd quarter. Engineers Gate Manager LP now owns 49,829 shares of the specialty retailer’s stock valued at $529,000 after purchasing an additional 10,249 shares during the last quarter. Finally, Ieq Capital LLC bought a new stake in Medifast in the 2nd quarter valued at about $114,000. 95.51% of the stock is currently owned by institutional investors.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.

The company’s product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company’s direct-selling model.

Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels.